Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Cytosorbents
CTSO
Cytosorbents
Healthcare Pricing And Regulation Will Stunt Prospects Despite Slight Hope
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
16 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.00
9.4% undervalued
intrinsic discount
16 Aug
US$0.91
1Y
-15.3%
7D
-17.6%
Loading
1Y
-15.3%
7D
-17.6%
Author's Valuation
US$1.0
9.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.0
9.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-36m
77m
2014
2017
2020
2023
2025
2026
2028
Revenue US$76.7m
Earnings US$9.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
28.55%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.54%
Calculation
US$9.53m
Earnings '28
x
12.84x
PE Ratio '28
=
US$122.34m
Market Cap '28
US$122.34m
Market Cap '28
/
96.22m
No. shares '28
=
US$1.27
Share Price '28
US$1.27
Share Price '28
Discounted to 2025 @ 8.33% p.a.
=
US$1.00
Fair Value '25
